Profile http://med.stanford.edu/profiles/Susan_Knox/ Email this page Printer friendly version

Key Documents

NIH Biosketch available Online

Curriculum Vitae available Online

Susan Knox

Associate Professor, Radiation Oncology - Radiation Therapy
Member, Bio-X
Member, Cancer Center

Contact Information

Clinical Offices

Radiation Therapy 875 Blake Wilbur Dr Clinic D Stanford, CA 94305-5847
Telephone Work (650) 723-6171 Fax (650) 725-8231
Academic Offices

Personal Information
Email sknox@stanford.edu
Not for medical emergencies or patient use

Clinical Focus

Cancer > Radiation Oncology
Cancer > Radiation Oncology > Radiation Therapy
Radiation Oncology
Radiation Therapy

Administrative Appointments

Associate Professor (University Tenure Line), Stanford Univ. Sch. of Medicine , (1997– 2008 )
Assistant Professor (University Tenure Line), Stanford Univ. Sch. of Medicine , (1990– 1997 )
Assistant Dean for Medical Student Advising, Stanford Univ. Sch. of Medicine , (2002– 2008 )
Member, Oncological Sciences Study Section Boundaries Team , (2001– 2001 )
Member, Clinical Oncology Study Section , (2001– 2004 )
Reviewer, External Advisory Committee for NIH grant U54 CA 90788 , (2001– 2006 )
Reviewer, Cancer Research UK , (2002– 2008 )
Reviewer, Advisory Board NIH T32 CA09695 , (2005– 2008 )
Editorial Board Member, Antibody, Immunoconjugates and Radiopharmaceuticals , (1992– 1995 )
Editorial Board Member, Cancer Biotherapy and Radiopharmaceuticals , (1996– 2008 )
Associate Editor, Radiation Research , (2000– 2003 )
Associate Editor, Journal of Clinical Oncology , (2003– 2006 )
Executive Committee, Clinical Cancer Center , (2003– 2008 )
Chair, Data and Safety Monitoring Committee, Stanford Clinical Trials Office, Cancer Center , (2003– 2003 )
Director, Core: Protocol Review and Monitoring System, Stanford Cancer Center , (2004– 2008 )
Medical Education Leadership Group, Stanford Cancer Center , (2004– 2008 )
RIT Advisory Board, Society Nuclear Medicine , (2006– 2008 )
Committee on the State of Science in Nuclear Medicine, Subcommittee on Targeted Radiotherapy, The National Academies , (2006– 2008 )
Item Writer of the written examination in the category of Radiobiology, American Board of Radiology , (2007– 2007 )
The Molecular Therapeutics Program, Cancer Center , (2008– 2008 )

Honors and Awards

Clinical Oncology Career Development Award, American Cancer Society (1991-94)
Lazard Faculty Scholar, Lazard Faculty (1992-93)
Board of Governors, Stanford Medical Alumni Association (2000-2008)
Charles F. Kettering Selection Committee, General Motors Cancer Research Foundation (2000-2002)
Elected Councilor Medicine, Radiation Research Society (2003)
President, Alumni Association, Stanford University School of Medicine (2005-2007)

Professional Education

SUMC - Graduate Medical Education (1990) CA
SUMC - Graduate Medical Education (1989) CA
UC Davis Medical Center (1986) CA
Stanford University School of Medicine (1985) CA
Resident, Stanford Univ. Hospital Medical Oncology (1990)
Post Doc Fellow, Stanford Univ. Hospital Medical Oncology (1989)
Medical Intern, UC Davis, California (1986)
Post-Doc Fellow/Res. Assist., Stanford Univ. Hospital Medical Oncology (1989)
MD, Stanford University (1985)
Post-Doc Res. Immunologist, UC Davis, California Energy-Related Health Research
PhD, UC Davis, California (1980)
AB, UC Berkeley, California, (1974)

Postdoctoral Advisees

Junqiang Tian

Graduate & Fellowship Program Affiliations

Web Site Links

http://www.stanford.edu/group/RIT

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities.

Consulting: InterWest Partners
Equity: InterWest Partners

Research Interests

- Radioimmunotherapy (RIT) and Systemically Targeted Radiation Therapy
- Low Dose Rate Effects
- Radioprotective Agents, Growth Factors/Receptors
- Oncogenes, Apoptosis & Radiosensitivity
- Apoptosis and Signal Transduction Pathways
- Effects of Radiation on the Immune Response
- Biological Response Modifiers and Novel Targeted Radiosensitizers
- Non-Hodgkin's Lymphomas
- Mycosis Fungoides
- Breast and Prostate Cancer
- Radiation as a component of Tumor Vaccine Strategies

Clinical Trials

Publications

Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Ning S, Knox SJ, Harsh GR, Culler MD, Katznelson L. Endocr Relat Cancer. 2009; 16 (3): 1045-55
(131)I-Tositumomab (Bexxar(R)) vs. (90)Y-Ibritumomab (Zevalin(R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma. Iagaru A, Mittra ES, Ganjoo K, Knox SJ, Goris ML. Mol Imaging Biol. 2009;
Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Bhattacharyya RS, Husbeck B, Feldman D, Knox SJ. Int J Radiat Oncol Biol Phys. 2008; 72 (3): 935-40
Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Ning S, Nemeth JA, Hanson RL, Forsythe K, Knox SJ. Mol Cancer Ther. 2008; 7 (6): 1569-78
Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Cancer. 2007; 110 (3): 477-88
Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis. Ning S, Chen Z, Dirks A, Husbeck B, Hsu M, Bedogni B, O'Neill M, Powell MB, Knox SJ. Radiat Res. 2007; 168 (1): 125-33
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, Whittaker S, Illidge TM, Schwarz T, Kaufmann R, Cooper K, Knudsen KM, Lisby S, Baadsgaard O, Knox SJ. Blood. 2007; 109 (11): 4655-62
MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy? Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. J Nucl Med. 2007; 48 (10): 1683-91
Radiation sensitization with redox modulators: a promising approach. Rosenberg A, Knox S. Int J Radiat Oncol Biol Phys. 2006; 64 (2): 343-54
Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. Ning S, Knox SJ. Int J Radiat Oncol Biol Phys. 2006; 65 (2): 493-8
Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Husbeck B, Bhattacharyya RS, Feldman D, Knox SJ. Mol Cancer Ther. 2006; 5 (8): 2078-85
Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Street HH, Goris ML, Fisher GA, Wessels BW, Cho C, Hernandez C, Zhu HJ, Zhang Y, Nangiana JS, Shan JS, Roberts K, Knox SJ. Cancer Biother Radiopharm. 2006; 21 (3): 243-56
Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Meredith RF, Knox SJ. Int J Radiat Oncol Biol Phys. 2006; 66 (2 Suppl): S15-22
Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation. Patel DA, Kochanski J, Suen AW, Fajardo LF, Hancock SL, Knox SJ. Cancer. 2006; 106 (3): 718-25
Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Husbeck B, Nonn L, Peehl DM, Knox SJ. Prostate. 2006; 66 (2): 218-25
Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia. Ning S, Hartley C, Molineux G, Knox SJ. Cancer Res. 2005; 65 (1): 284-90
Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Husbeck B, Peehl DM, Knox SJ. Free Radic Biol Med. 2005; 38 (1): 50-7
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, Wahl RL. J Clin Oncol. 2005; 23 (31): 7985-93
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M. J Clin Oncol. 2005; 23 (30): 7565-73
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM, Capizzi RL. Blood. 2005; 105 (12): 4576-82
Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Hernandez MC, Knox SJ. Int J Radiat Oncol Biol Phys. 2004; 59 (5): 1274-87
A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ. Int J Radiat Oncol Biol Phys. 2004; 58 (4): 1215-27
Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors. Maxim PG, Carson JJ, Ning S, Knox SJ, Boyer AL, Hsu CP, Benaron DA, Walleczek J. Radiat Res. 2004; 162 (2): 185-93
Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. Ning S, Knox SJ. Int J Radiat Oncol Biol Phys. 2004; 60 (1): 197-203
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, Meredith RF. Blood. 2004; 104 (1): 227-36
Dosimetry model for radioactivity localized to intestinal mucosa. Fisher D, Rajon D, Breitz H, Goris M, Bolch W, Knox S. Cancer Biother Radiopharm. 2004; 19 (3): 293-307
Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier. Wartchow CA, Alters SE, Garzone PD, Li L, Choi S, DeChene NE, Doede T, Huang L, Pease JS, Shen Z, Knox SJ, Cleland JL. Pharm Res. 2004; 21 (10): 1880-5
The radioisotope contributes significantly to the activity of radioimmunotherapy. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ. Clin Cancer Res. 2004; 10 (23): 7792-8
Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma. Yuen AR, Higgins JP, Baker R, Kamel OW, Warnke RA, Knox SJ. Hum Pathol. 2003; 34 (4): 381-4
Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells. Li L, Steinauer KK, Dirks AJ, Husbeck B, Gibbs I, Knox SJ. Radiat Res. 2003; 160 (6): 617-21
Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin). Hernandez MC, Knox SJ. Semin Oncol. 2003; 30 (6 Suppl 17): 6-10
Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Armstrong JS, Steinauer KK, Hornung B, Irish JM, Lecane P, Birrell GW, Peehl DM, Knox SJ. Cell Death Differ. 2002; 9 (3): 252-63
The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Ning S, Laird D, Cherrington JM, Knox SJ. Radiat Res. 2002; 157 (1): 45-51
Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell line PW. Armstrong JS, Hornung B, Lecane P, Jones DP, Knox SJ. Biochem Biophys Res Commun. 2001; 289 (5): 973-8
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM. J Clin Oncol. 2001; 19 (19): 3918-28
Bcl-2 inhibits apoptosis induced by mitochondrial uncoupling but does not prevent mitochondrial transmembrane depolarization. Armstrong JS, Steinauer KK, French J, Killoran PL, Walleczek J, Kochanski J, Knox SJ. Exp Cell Res. 2001; 262 (2): 170-9
Radioimmunotherapy of B-cell NHL. Meredith RF, Knox SJ. Curr Pharm Biotechnol. 2001; 2 (4): 327-39
Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University. Murtha AD, Rupnow BA, Hansosn J, Knox SJ, Hoppe R. Int J Radiat Oncol Biol Phys. 2001; 49 (1): 3-15
Introduction Knox SJ, Semin Radiat Oncol. 2000; 10 (2): 71-2
Clinical radioimmunotherapy. Knox SJ, Meredith RF. Semin Radiat Oncol. 2000; 10 (2): 73-93
Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Steinauer KK, Gibbs I, Ning S, French JN, Armstrong J, Knox SJ. Int J Radiat Oncol Biol Phys. 2000; 48 (2): 325-8
Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96365-induced apoptosis. Williams SS, French JN, Gilbert M, Rangaswami AA, Walleczek J, Knox SJ. Cancer Res. 2000; 60 (16): 4358-61
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM. Clin Cancer Res. 2000; 6 (2): 406-14
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS. J Clin Oncol. 2000; 18 (6): 1316-23
Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, Weiden PL. Cancer Biother Radiopharm. 1999; 14 (5): 381-95
G2/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation. Ning S, Knox SJ. Radiat Res. 1999; 151 (6): 659-69
Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system. Ning S, Yu N, Brown DM, Kanekal S, Knox SJ. Radiother Oncol. 1999; 50 (2): 215-23
The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Rupnow BA, Knox SJ. Apoptosis. 1999; 4 (2): 115-43
p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts. Rupnow BA, Alarcon RM, Giaccia AJ, Knox SJ. Cell Death Differ. 1998; 5 (2): 141-7
Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Ning S, Shui C, Khan WB, Benson W, Lacey DL, Knox SJ. Int J Radiat Oncol Biol Phys. 1998; 40 (1): 177-87
Myc activation reduces fibroblast clonogenicity via an apoptotic mechanism that can be suppressed by a soluble paracrine factor. Rupnow BA, Murtha AD, Chen E, Knox SJ. Cancer Lett. 1998; 127 (1-2): 211-9
Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Rupnow BA, Murtha AD, Alarcon RM, Giaccia AJ, Knox SJ. Cancer Res. 1998; 58 (9): 1779-84
A prospective study of radiation therapy-associated thrombocytopenia. Knox SJ, Varghese A, Khan W, Chen E, MacManus M, Ray G, Lee K, Lamborn KR. Blood. 1997; 90 (10): 4237-8
Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Mac Manus M, Lamborn K, Khan W, Varghese A, Graef L, Knox S. Blood. 1997; 89 (7): 2303-10
Influence of Bcl-2 overexpression on Na+/K(+)-ATPase pump activity: correlation with radiation-induced programmed cell death. Gilbert M, Knox S. J Cell Physiol. 1997; 171 (3): 299-304
Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. Khan WB, Shui C, Ning S, Knox SJ. Radiat Res. 1997; 148 (3): 248-53
Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Ning S, Trisler K, Wessels BW, Knox SJ. Cancer. 1997; 80 (12 Suppl): 2519-28
Association of BCL-2 with membrane hyperpolarization and radioresistance. Gilbert MS, Saad AH, Rupnow BA, Knox SJ. J Cell Physiol. 1996; 168 (1): 114-22
Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel. Ning S, Trisler K, Brown DM, Yu NY, Kanekal S, Lundsten MJ, Knox SJ. Radiother Oncol. 1996; 39 (2): 179-89
Modulation of c-Myc activity and apoptosis in vivo. Alarcon RM, Rupnow BA, Graeber TG, Knox SJ, Giaccia AJ. Cancer Res. 1996; 56 (19): 4315-9
Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, Becker M, Marquez C, Knox S. Clin Cancer Res. 1996; 2 (8): 1289-97
Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (Tirapazamine). Gilbert MS, Rupnow BA, Ramirez DA, Trisler KD, Knox SJ. Cell Death Differ. 1996; 3 (2): 215-22
Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Knox S, Hoppe RT, Maloney D, Gibbs I, Fowler S, Marquez C, Cornbleet PJ, Levy R. Blood. 1996; 87 (3): 893-9
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-López A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R. Clin Cancer Res. 1996; 2 (3): 457-70
Stem cell factor enhances the survival of murine intestinal stem cells after photon irradiation. Leigh BR, Khan W, Hancock SL, Knox SJ. Radiat Res. 1995; 142 (1): 12-5
Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Becker M, Hoppe RT, Knox SJ. Int J Radiat Oncol Biol Phys. 1995; 32 (5): 1445-9
Effects of stem cell factor on the growth and radiation survival of tumor cells. Shui C, Khan WB, Leigh BR, Turner AM, Wilder RB, Knox SJ. Cancer Res. 1995; 55 (15): 3431-7
Overview of studies on experimental radioimmunotherapy. Knox SJ, Cancer Res. 1995; 55 (23 Suppl): 5832s-5836s
Radioimmunotherapy of the Non-Hodgkin's Lymphomas. Knox SJ, Semin Radiat Oncol. 1995; 5 (4): 331-341
The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Wilder RB, McGann JK, Sutherland WR, Waller EK, Minchinton AI, Goris ML, Knox SJ. Int J Radiat Oncol Biol Phys. 1994; 28 (1): 119-26
Effect of filgrastim (G-CSF) in Hodgkin's disease patients treated with radiation therapy. Knox SJ, Fowler S, Marquez C, Hoppe RT. Int J Radiat Oncol Biol Phys. 1994; 28 (2): 445-50
Stem cell factor enhances the survival of irradiated human bone marrow maintained in SCID mice. Leigh BR, Webb S, Hancock SL, Knox SJ. Stem Cells. 1994; 12 (4): 430-5
Organ modeling in the quantitation of planar images for distribution studies. Goris ML, Knox SA, Nielsen KR, Bouillant O. Cancer. 1994; 73 (3 Suppl): 919-22
Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Langmuir VK, Fowler JF, Knox SJ, Wessels BW, Sutherland RM, Wong JY. Med Phys. 1993 Mar-Apr; 20 (2 Pt 2): 601-10
The effect of stem cell factor on irradiated human bone marrow. Leigh BR, Hancock SL, Knox SJ. Cancer Res. 1993; 53 (17): 3857-9
Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters. Knox SJ, Sutherland W, Goris ML. Radiat Res. 1993; 135 (1): 24-31
Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts. Wilder RB, Langmuir VK, Mendonca HL, Goris ML, Knox SJ. Cancer Res. 1993; 53 (13): 3022-7
Response to letter by A. E. Amin regarding tumour size dependence of relative efficacy of radioimmunotherapy and external beam irradiation in tumour treatment. Knox SJ, Goris ML, Wessels BW. Radiotherapy Oncology. 1993; 25 219-220
Determinants of low dose rate effects associated with radioimmunotherapy. Knox SJ, Sutherland W, Goris ML. Antibody Immunoconjugates and Radiopharmaceuticals. 1993; 6 197-207
Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Knox SJ, Goris ML, Wessels BW. Radiother Oncol. 1992; 23 (2): 111-7
The effect of unlabelled monoclonal antibody (mAb) on the biodistribution of 131I-anti-idiotype mAb in murine B cell lymphoma. Schiele J, Knox SJ, Ruehl W, Goris ML. Radiother Oncol. 1992; 24 (3): 169-76
The biodistribution of 111In-anti-bFGF in a variety of tumors. Correlation with cell-binding assays. Knox SJ, Brown JM, McGann J, Sutherland W, Goris ML, Herblin WF, Gross JL. Ann N Y Acad Sci. 1991; 638 497-502
Results of the 1989 Association of Residents in Radiation Oncology survey. Corn BW, Taylor BW, Knox SJ, Martz KL, Flynn DF. Int J Radiat Oncol Biol Phys. 1991; 20 (6): 1363-7
Mycosis fungoides arthropathy. Berger RG, Knox SJ, Levy R, Sklar JL, Cohen P, Reichert T. Ann Intern Med. 1991; 114 (7): 571-2
Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Knox SJ, Levy R, Hodgkinson S, Bell R, Brown S, Wood GS, Hoppe R, Abel EA, Steinman L, Berger RG. Blood. 1991; 77 (1): 20-30
The changing face of radiation oncology. Meredith RF, Halberg FE, Knox SJ. South Med J. 1990; 83 (4): 488
Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Knox SJ, Levy R, Miller RA, Uhland W, Schiele J, Ruehl W, Finston R, Day-Lollini P, Goris ML. Cancer Res. 1990; 50 (16): 4935-40
Hyperthermia and radiation therapy in the treatment of recurrent Merkel cell tumors. Knox SJ, Kapp DS. Cancer. 1988; 62 (8): 1479-86
Effect of thymopoietin and interleukin 2 on depressed mitogenic responsiveness and colony formation of lymphocytes from patients with preleukemia. Knox SJ, Rosenblatt LS, Anderson RW, Greenberg BR. Thymus. 1986; 8 (1-2): 33-44
Two independent pathways of helper activity provided by a single T cell clone. Shigeta M, Takahara S, Knox SJ, Ishihara T, Vitetta ES, Fathman CG. J Immunol. 1986; 136 (1): 34-8
Relation of age to lymphocyte radiosensitivity in vitro. Knox SJ, Shifrine M, Rosenblatt LS, Reeves JD, Woerner S. Health Phys. 1984; 46 (2): 431-4
Lymphocyte abnormalities in preleukemia--I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. Anderson RW, Volsky DJ, Greenberg B, Knox SJ, Bechtold T, Kuszynski C, Harada S, Purtilo DT. Leuk Res. 1983; 7 (3): 389-95
Studies of T-lymphocytes in preleukemic disorders and acute nonlymphocytic leukemia: in vitro radiosensitivity, mitogenic responsiveness, colony formation, and enumeration of lymphocytic subpopulations. Knox SJ, Greenberg BR, Anderson RW, Rosenblatt LS. Blood. 1983; 61 (3): 449-55
Growth of human T lymphocyte colonies from whole blood: culture requirements and applications. Knox SJ, Wilson FD, Greenberg BR, Shifrine M. J Cell Biochem. 1982; 18 (1): 15-24
Assessment of the in vitro radiosensitivity of human peripheral blood lymphocytes. Knox SJ, Shifrine M, Rosenblatt LS. Radiat Res. 1982; 89 (3): 575-89
Growth of macrophage colonies from normal canine peripheral blood: morphological, cytochemical and functional parameters. Knox SJ, Wilson FD, Miller CH, Rosenblatt LS, Shifrine M. Stem Cells. 1982; 1 (6): 325-44
Radiation-induced inhibition of human lymphocyte blastogenesis: the effect of superoxide dismutase and catalase. Knox SJ, Misra HP, Shifrine M, Rosenblatt LS. Int J Radiat Biol Relat Stud Phys Chem Med. 1982; 41 (3): 283-94
The selective growth of human T lymphocyte colonies from whole blood in a semisolid culture system. Knox SJ, Shifrine M, Wilson FD, Rosenblatt LS. Exp Hematol. 1981; 9 (9): 926-37
Increased radiosensitivity of a subpopulation ot T-lymphocyte progenitors from patients with Fanconi's anemia. Knox SJ, Wilson FD, Greenberg BR, Shifrine M, Rosenblatt LS, Reeves JD, Misra H. Blood. 1981; 57 (6): 1043-8
Cytogenetics and granulopoietic effects of bone marrow fibroblastic cells in Fanconi's anaemia. Greenberg BR, Wilson FD, Woo L, Knox S, Jenks H, Taplett J. Br J Haematol. 1981; 48 (1): 85-93
Cell-mediated immunity in the dog in relation to disease: A review. Knox SJ, Shifrine M. Comp Immun Microbiol Infect Dis. 1980; 2 405-415
A "whole-blood" technique for the quantitation of canine "T-lymphocyte" progenitors using a semisolid culture system. Wilson FD, Dyck JA, Knox SJ, Shifrine M. Exp Hematol. 1980; 8 (8): 1031-9
Susceptibility of clinical isolates of Pseudomonas aeruginosa to antimicrobial agents. Hirsh DC, Wiger N, Knox SJ. Pharmacol Ther. 1979; 2 275-278
Pharmacokinetics of penicillin G in the turkey. Hirsh DC, Knox SJ, Conzelman GM, Wiger N. Am J Vet Res. 1978; 39 (7): 1219-21